khellin has been researched along with Chronic Illness in 21 studies
Khellin: A vasodilator that also has bronchodilatory action. It has been employed in the treatment of angina pectoris, in the treatment of asthma, and in conjunction with ultraviolet light A, has been tried in the treatment of vitiligo. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1024)
khellin : A furanochrome in which the basic tricyclic skeleton is substituted at positions 4 and 9 with methoxy groups and at position 7 with a methyl group. A major constituent of the plant Ammi visnaga it is a herbal folk medicine used for various illnesses, its main effect being as a vasodilator.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Severe adverse effects were not observed." | 2.79 | Adjuvant single-fraction radiotherapy is safe and effective for intractable keloids. ( Chang, H; Ha, SW; Kim, IH; Song, C; Wu, HG, 2014) |
| "Keloids are considered as benign fibroproliferative skin tumors growing beyond the site of the original dermal injury." | 2.61 | Understanding Keloid Pathobiology From a Quasi-Neoplastic Perspective: Less of a Scar and More of a Chronic Inflammatory Disease With Cancer-Like Tendencies. ( Bayat, A; Khumalo, N; Tan, S, 2019) |
| "Autophagy induction by rapamycin treatment in keloid fibroblasts effectively suppressed expression levels of Notch1 and NLRP3 inflammasome proteins." | 1.56 | Contribution of Autophagy-Notch1-Mediated NLRP3 Inflammasome Activation to Chronic Inflammation and Fibrosis in Keloid Fibroblasts. ( Kang, H; Kim, JE; Kim, SK; Lee, DG; Lee, KJ; Lee, S; Lee, YJ; Park, H; Park, SH, 2020) |
| "Keloid is a clinically intractable fibro-proliferative disease that spreads beyond the original scar or lesion." | 1.39 | Keloid formation on the great toe after chronic paronychia secondary to ingrown nail. ( Burm, JS; Lee, KW; Yang, WY, 2013) |
| "In the event that a keloid is presented in isolation, chronic osteomyelitis should be considered as a differential diagnosis, and a high index of suspicion is required in order to establish the diagnosis." | 1.37 | Chronic osteomyelitis in the lower extremity predisposing to the unusual formation of keloids. ( Olabanji, JK; Oladele, AO; Orimolade, EA; Yusuf, MB, 2011) |
| "Verneuil's disease (hidradenitis suppurativa) is a chronic inflammatory, suppurating and fistulizing disease of apocrine sweat gland-bearing skin." | 1.31 | [Surgical treatment of Verneuil's disease (hidradenitis suppurativa): 15 cases]. ( Destrumelle, N; Dupond, AS; Humbert, P; Lamfichekh, N; Mantion, G; Runser, C, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (47.62) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| SILBER, EN | 1 |
| SNIDER, GL | 1 |
| GOLDBERG, H | 1 |
| KATZ, LN | 2 |
| RADNER, DB | 1 |
| ROSENMAN, RH | 1 |
| FISHMAN, AP | 1 |
| KAPLAN, SR | 1 |
| LEVIN, HG | 1 |
| Virchow, C | 1 |
| Debelic, M | 1 |
| Klein, HG | 1 |
| Tan, S | 1 |
| Khumalo, N | 1 |
| Bayat, A | 1 |
| Lee, S | 1 |
| Kim, SK | 1 |
| Park, H | 1 |
| Lee, YJ | 1 |
| Park, SH | 1 |
| Lee, KJ | 1 |
| Lee, DG | 1 |
| Kang, H | 1 |
| Kim, JE | 1 |
| Lee, KW | 1 |
| Burm, JS | 1 |
| Yang, WY | 1 |
| Kanumuri, VV | 1 |
| Raikundalia, MD | 1 |
| Khan, MN | 1 |
| Husain, Q | 1 |
| Vasquez, A | 1 |
| Eloy, JA | 1 |
| Song, C | 1 |
| Wu, HG | 1 |
| Chang, H | 1 |
| Kim, IH | 1 |
| Ha, SW | 1 |
| Thiboutot, D | 1 |
| Gollnick, H | 1 |
| Bettoli, V | 1 |
| Dréno, B | 1 |
| Kang, S | 1 |
| Leyden, JJ | 1 |
| Shalita, AR | 1 |
| Lozada, VT | 1 |
| Berson, D | 1 |
| Finlay, A | 1 |
| Goh, CL | 1 |
| Herane, MI | 1 |
| Kaminsky, A | 1 |
| Kubba, R | 1 |
| Layton, A | 1 |
| Miyachi, Y | 1 |
| Perez, M | 1 |
| Martin, JP | 1 |
| Ramos-E-Silva, M | 1 |
| See, JA | 1 |
| Shear, N | 1 |
| Wolf, J | 1 |
| Davison, SP | 1 |
| Sobanko, JF | 1 |
| Clemens, MW | 1 |
| Orimolade, EA | 1 |
| Olabanji, JK | 1 |
| Oladele, AO | 1 |
| Yusuf, MB | 1 |
| Lebedeva, LV | 1 |
| Nikolaeva, NV | 1 |
| Katz, BE | 1 |
| Kim, WJ | 1 |
| Lamfichekh, N | 1 |
| Dupond, AS | 1 |
| Destrumelle, N | 1 |
| Runser, C | 1 |
| Humbert, P | 1 |
| Mantion, G | 1 |
| Jaramillo, D | 1 |
| Cortés, A | 1 |
| Restrepo, A | 1 |
| Builes, M | 1 |
| Robledo, M | 1 |
| Zabolotskiĭ, AT | 1 |
| Sizov, VM | 1 |
| Lositskaia, VM | 1 |
| Achten, G | 1 |
| Bourlond, A | 1 |
| Haven, E | 1 |
| Lapière, CM | 1 |
| Piérard, J | 1 |
| Reynaers, H | 1 |
| Sharapova, GIa | 1 |
| Khamaganova, AV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Safety and Efficacy of Tazarotene 0.1% Plus Clindamycin 1% Gel vs. Adapalene 0.1% Plus Clindamycin 1% Gel in the Treatment of Facial Acne Vulgaris: A Randomized Controlled Trial[NCT02721173] | Phase 4 | 60 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Autologous Fat Cells Transfer for the Treatment of Atrophic Post Acne Scars: Clinical Trail[NCT05028283] | 69 participants (Actual) | Interventional | 2021-08-19 | Completed | |||
| A Phase 1B Dose Escalating Study of the Safety, Short-Term Engraftment and Action of a Singly-Applied NB01 in Adults With Moderate Acne[NCT03450369] | Phase 1 | 10 participants (Actual) | Interventional | 2018-01-24 | Completed | ||
| Serum apelin12 in Acne Vulgaris[NCT03480503] | 90 participants (Anticipated) | Observational | 2018-05-31 | Not yet recruiting | |||
| Comparison of the Effectiveness in Prevention of Hypertrophic Scars or Keloids Between Silicone Sheet, Silicone Gel and Paper Steri-strip-A Randomised Controlled Trial.[NCT00849004] | 75 participants (Anticipated) | Interventional | 2009-03-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Engraftment is defined as the percentage of bacteria recovered from hair follicles that are health-associated (NB01) as measured with proprietary quantitative polymerase chain assays. Successful follicular engraftment, defined as both deoR/PanBac >40% and Cas5/PanBac >40% in the Day 2 (24H) ) Biore Strip samples. Cas5/PanBac and deoR/PanBac are the percentages of bacteria in a sample containing the CRISPR associated protein Cas5 and a repressor of porphyrin production deoR, respectively. Pan-Bacterial (PanBac) is a loci found in nearly all bacteria found on the face and thus serves as the denominator to calculate the percentage of bacteria with any loci. (NCT03450369)
Timeframe: 2 Months
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Dose | 2 |
| High Dose | 1 |
To determine longevity of the live biotherapeutic after a single application, swab samples were collected at Baseline, 6, 24 and 48 hours after application, and genotyped as above. For each participant the absolute change, from Baseline, in the percentage of the two loci present in the live biotherapeutic (deoR and Cas5) were calculated. A significant positive change is indicative of the continued presence of the live biotherapeutic. (NCT03450369)
Timeframe: From Baseline to 48 hours after application
| Intervention | % of total bacteria w/ genotype (Mean) | |||||
|---|---|---|---|---|---|---|
| Genotype 1 (deoR), 6 hours | Genotype 1 (deoR), 24 hours | Genotype 1 (deoR), 48 hours | Genotype 2 (Cas 5), 6 hours | Genotype 2 (Cas 5), 24 hours | Genotype 2 (Cas 5), 48 hours | |
| High Dose | 51.2 | 5.2 | 2.8 | 48.4 | 4.4 | 1.8 |
| Low Dose | -0.4 | -4.2 | 13.8 | 12.8 | 3.4 | 3.2 |
Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Conjunctival Injection. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Screening, scale = 0 (none) | Day 1 (0 hours), scale = 0 (none) | Day 1 (6 hours), scale = 0 (none) | Day 2, scale = 0 (none) | Day 3, scale = 0 (none) | Day 7, scale = 0 (none) | Day 28, scale = 0 (none) | |
| High Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Low Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Hyperpigmentation. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Screening, scale = 0 (none) | Day 1 (0 hours), scale = 0 (none) | Day 1 (6 hours), scale = 0 (none) | Day 2, scale = 0 (none) | Day 3, scale = 0 (none) | Day 7, scale = 0 (none) | Day 28, scale = 0 (none) | |
| High Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Low Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Irritant/Allergic Contact Dermatitis. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Screening, scale = 0 (none) | Day 1 (0 hours), scale = 0 (none) | Day 1 (6 hours), scale = 0 (none) | Day 2, scale = 0 (none) | Day 3, scale = 0 (none) | Day 7, scale = 0 (none) | Day 28, scale = 0 (none) | |
| High Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Low Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Mucosal Toxicity. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Screening, scale = 0 (none) | Day 1 (0 hours), scale = 0 (none) | Day 1 (6 hours), scale = 0 (none) | Day 2, scale = 0 (none) | Day 3, scale = 0 (none) | Day 7, scale = 0 (none) | Day 28, scale = 0 (none) | |
| High Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Low Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Ocular Irritation. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Screening, scale = 0 (none) | Day 1 (0 hours), scale = 0 (none) | Day 1 (6 hours), scale = 0 (none) | Day 2, scale = 0 (none) | Day 3, scale = 0 (none) | Day 7, scale = 0 (none) | Day 28, scale = 0 (none) | |
| High Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Low Dose | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Skin Dryness. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | Participants (Count of Participants) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Screening, scale = 0 (none) | Screening, scale = 1 (slight) | Day 1 (0 hours), scale = 0 (none) | Day 1 (0 hours), scale = 1 (slight) | Day 1 (6 hours), scale = 0 (none) | Day 1 (6 hours), scale = 1 (slight) | Day 2, scale = 0 (none) | Day 2, scale = 1 (slight) | Day 3, scale = 0 (none) | Day 3, scale = 1 (slight) | Day 7, scale = 0 (none) | Day 28, scale = 0 (none) | Day 28, scale = 1 (slight) | |
| High Dose | 5 | 0 | 5 | 0 | 5 | 0 | 5 | 0 | 5 | 0 | 5 | 5 | 0 |
| Low Dose | 4 | 1 | 4 | 1 | 4 | 1 | 4 | 1 | 4 | 1 | 5 | 3 | 2 |
Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Skin Erythema. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | Participants (Count of Participants) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Screening, scale = 0 (none) | Screening, scale = 1 (slight) | Day 1 (0 hours), scale = 0 (none) | Day 1 (0 hours), scale = 1 (slight) | Day 1 (0 hours), scale = 2 (moderate) | Day 1 (6 hours), scale = 0 (none) | Day 1 (6 hours), scale = 1 (slight) | Day 1 (6 hours), scale = 2 (moderate) | Day 2, scale = 0 (none) | Day 2, scale = 1 (slight) | Day 3, scale = 0 (none) | Day 3, scale = 1 (slight) | Day 7, scale = 0 (none) | Day 7, scale = 1 (slight) | Day 28, scale = 0 (none) | |
| High Dose | 5 | 0 | 5 | 0 | 0 | 5 | 0 | 0 | 5 | 0 | 5 | 0 | 5 | 0 | 5 |
| Low Dose | 2 | 3 | 3 | 1 | 1 | 3 | 1 | 1 | 4 | 1 | 4 | 1 | 4 | 1 | 5 |
Safety profile and tolerability of a singly applied NB01 using the Investigator Assessment of Tolerability Scoring (0 = None; 1 = Slight; 2 = Moderate; 3 = Intense) for Skin Peeling. Reference: ClinicalTrials.gov: Investigator Assessment Tolerability Scoring: A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Acne. (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Screening, scale = 0 (none) | Screening, scale = 1 (slight) | Day 1 (0 hours), scale = 0 (none) | Day 1 (0 hours), scale = 1 (slight) | Day 1 (6 hours), scale = 0 (none) | Day 1 (6 hours), scale = 1 (slight) | Day 2, scale = 0 (none) | Day 3, scale = 0 (none) | Day 7, scale = 0 (none) | Day 28, scale = 0 (none) | |
| High Dose | 5 | 0 | 5 | 0 | 5 | 0 | 5 | 5 | 5 | 5 |
| Low Dose | 3 | 2 | 4 | 1 | 4 | 1 | 5 | 5 | 5 | 5 |
"Number of participants with a changed Investigator Global Assessment (IGA) score after single application of NB01; positive number if grade is reduced (e.g. from 3 to 2) or negative number is IGA grade increased.~The Investigator Global Assessment 5-Point Score is a standard FDA acne assessment tool with scoring as follows:~Grade 0-Clear (Clear skin with no inflammatory or non-inflammatory lesions. The category of clear should represent true absence of disease) Grade1-Almost Clear (A few scattered comedones and no more than one small papule) Grade 2-Mild (Some comedones, some papules and pustules; no nodules) Grade 3-Moderate (Many comedones, papules and pustules; one nodule may be present) Grade 4-Severe (Covered with comedones, numerous papules and pustules and no more than a few nodular lesions)" (NCT03450369)
Timeframe: 28 Days
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Participants with changed IGA @ 6 hours | Participants with changed IGA @ 1 day | Participants with changed IGA @ 2 days | Participants with changed IGA @ 6 days | Participants with changed IGA @ 28 days | |
| High Dose | 0 | 0 | 0 | 0 | 0 |
| Low Dose | 0 | 0 | 0 | 0 | 2 |
Absolute Lesion Count: All Lesions for the Whole Face; with higher numbers of lesion representing worsening or more severe acne (NCT03450369)
Timeframe: From Screening to 28 days after application, typically 2 months
| Intervention | count of lesions (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Screening | Day 1 (0 hours) | Day 1 (6 hours) | Day 2 | Day 3 | Day 7 | Day 28 | |
| High Dose | 38.8 | 42.6 | 39.8 | 38.2 | 35.4 | 34.2 | 32.6 |
| Low Dose | 49.4 | 22.6 | 21.0 | 31.6 | 32.2 | 25.6 | 25.8 |
3 reviews available for khellin and Chronic Illness
| Article | Year |
|---|---|
Understanding Keloid Pathobiology From a Quasi-Neoplastic Perspective: Less of a Scar and More of a Chronic Inflammatory Disease With Cancer-Like Tendencies.
Topics: Animals; Chronic Disease; Humans; Inflammation; Keloid; Neoplasms | 2019 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group.
Topics: Acne Vulgaris; Administration, Oral; Administration, Topical; Algorithms; Anti-Bacterial Agents; Chr | 2009 |
Cellular signaling in tissue regeneration.
Topics: Animals; Cell Physiological Phenomena; Chemokines; Chronic Disease; Growth Substances; Humans; Keloi | 2000 |
2 trials available for khellin and Chronic Illness
| Article | Year |
|---|---|
Adjuvant single-fraction radiotherapy is safe and effective for intractable keloids.
Topics: Adult; Chronic Disease; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Humans; Ke | 2014 |
[Bufexamac cream and ointment for the treatment of various dermatoses].
Topics: Anti-Inflammatory Agents; Chemical Phenomena; Chemistry; Chronic Disease; Clinical Trials as Topic; | 1973 |
16 other studies available for khellin and Chronic Illness
| Article | Year |
|---|---|
The effect of khellin on cardio-pulmonary function in chronic pulmonary disease.
Topics: Chronic Disease; Heart; Khellin; Lung Diseases | 1951 |
Observations on the clinical use of visammin (khellin).
Topics: Angina Pectoris; Chronic Disease; Hypertension, Pulmonary; Khellin; Pulmonary Heart Disease | 1950 |
[Therapy of chronic-obstructive ailments of the respiratory tract].
Topics: Bronchitis; Chronic Disease; Humans; Injections, Intravenous; Khellin; Lung Diseases; Lung Diseases, | 1970 |
[Experiences in the treatment of bronchospastic diseases].
Topics: Adult; Aged; Asthma; Bronchitis; Bronchodilator Agents; Chronic Disease; Diphenhydramine; Ephedrine; | 1967 |
Contribution of Autophagy-Notch1-Mediated NLRP3 Inflammasome Activation to Chronic Inflammation and Fibrosis in Keloid Fibroblasts.
Topics: Adolescent; Adult; Aged; Autophagy; Chronic Disease; Female; Fibroblasts; Humans; Inflammasomes; Inf | 2020 |
Keloid formation on the great toe after chronic paronychia secondary to ingrown nail.
Topics: Chronic Disease; Female; Humans; Keloid; Nails, Ingrown; Paronychia; Secondary Prevention; Wound Hea | 2013 |
Clival keloid after nasopharyngeal radium irradiation masquerading as skull base malignancy.
Topics: Aged; Bone Diseases; Chronic Disease; Cranial Fossa, Posterior; Diagnosis, Differential; Humans; Kel | 2014 |
Use of a collagen-glycosaminoglycan copolymer (Integra) in combination with adjuvant treatments for reconstruction of severe chest keloids.
Topics: Adult; Aged; Anti-Inflammatory Agents; Chondroitin Sulfates; Chronic Disease; Collagen; Combined Mod | 2010 |
Chronic osteomyelitis in the lower extremity predisposing to the unusual formation of keloids.
Topics: Ankle; Child; Chronic Disease; Fibula; Humans; Inflammation; Keloid; Lower Extremity; Male; Nigeria; | 2011 |
[Contraindication of operations for keloid scars occurring after BCG administration].
Topics: Adolescent; BCG Vaccine; Child; Chronic Disease; Female; Humans; Keloid; Recurrence | 1981 |
Silicone gel sheeting in scar therapy.
Topics: Bandages; Chronic Disease; Cicatrix, Hypertrophic; Dermabrasion; Dermatitis, Irritant; Follow-Up Stu | 1995 |
[Surgical treatment of Verneuil's disease (hidradenitis suppurativa): 15 cases].
Topics: Abscess; Adult; Chronic Disease; Female; Fistula; Hidradenitis Suppurativa; Humans; Keloid; Male; Mi | 2001 |
Lobomycosis. Report of the eighth Colombian case and review of the literature.
Topics: Adult; Blastomycosis; Chronic Disease; Female; Humans; Keloid | 1976 |
[Surgical treatment of elephantiasis of the upper extremities].
Topics: Adolescent; Adult; Arm; Child; Child, Preschool; Chronic Disease; Elephantiasis; Female; Humans; Kel | 1975 |
[Effect of cryogenic action on the proteinase activity in patients with keloid and hypertrophic scars].
Topics: Adolescent; Adult; Child; Child, Preschool; Chronic Disease; Cicatrix; Cryosurgery; Endopeptidases; | 1988 |
[Treatment of some dermatoses by the intradermal injections of a 10 percent solution of quingamine].
Topics: Adult; Chloroquine; Chronic Disease; Female; Humans; Injections, Intradermal; Keloid; Lupus Erythema | 1973 |